Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...